Clinical Oversight Review Board (CORB) Criteria for Prescribing

Cabotegravir (Apretude)

Notes:

• * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Non-Formulary **cabotegravir** (**Apretude**) requires a clinical review. Appropriateness of therapy will be determined based on the following criteria:

- Prescribed by immune deficiency clinic (IDC) provider
 -AND-
- Prescribed for HIV pre-exposure prophylaxis (PrEP)
 -AND-
- Patient has a recent negative HIV antibody test and undetectable HIV-1 RNA viral load (VL)

-AND one of the following-

- Patient has allergy or intolerance* to emtricitabine/tenofovir disoproxil fumarate (TDF-FTC) and tenofovir-alafenamide / emtricitabine (TAF-FTC)
 -OR-
- Patient has a significant contraindication to both tenofovir alafenamide and tenofovir disoproxil fumarate defined as one of the following:
 - Kidney impairment defined by creatinine clearance (CrCl) less than 30 ml/min
 - Persistently increased serum creatinine from baseline while using TDF-FTC or TAF-FTC, defined as 2 or more lab results with an increase of 0.4 mg/dL
 - o Sustained proteinuria; sustained glucosuria not attributable to another cause

-OR-

- Members experiencing structural or individual level barriers to oral PrEP use based on the prescribing clinician's judgment
- Patient has chronic hepatitis B infection without indication for hepatitis B treatment
- Patient has needed more than 2 NPEP (non-occupational post-exposure) courses over 12 months due to poor adherence to oral PrEP
 OR-
- Patient has suboptimal adherence to daily oral PrEP with ongoing risk for HIV exposure (2 or more missed doses of oral PrEP/week)
 -OR-

kp.org

Revised: 01/12/23 Effective: 03/02/23 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest



Clinical Oversight Review Board (CORB) Criteria for Prescribing

Cabotegravir (Apretude)


 Members who have evidence of malabsorption from GI condition (e.g., sleeve gastrectomy, gastric bypass, terminal ileitis, celiac disease, severe chronic diarrhea)

-OR-

• Patient is a new member to Kaiser Permanente, is already stable on the drug

kp.org

Revised: 01/12/23 Effective: 03/02/23





All plans offered and underwritten by